title: [Experimental research on prevention and treatment of fatty liver rats with Abrus cantoniensis].
abstract: OBJECTIVE
  To investigate the effects of Abrus cantoniensis (AC) on blood lipid metabolism, pathomorphological change of the liver and fenestrae of liver sinus endothelial cell (LSEC) in fatty liver disease rats.
  
  
  METHODS
  SD rats were divided into 7 groups: blank control group,fatty liver model group, simvastatin group (7.2 mg/kg), Gynostemma pentaphyllum group (16.2 mg/kg), high dose (40 g/kg), middle dose (20 g/kg) and low dose (10 g/kg) of AC groups. All rats except blank control group were fed with high fat diet for the first 3 weeks, then treated with different conditions as previously mentioned for the next 3 weeks while keep on feeding with high fat diet. At the 43rd day,the abdominal aortic blood was collected for measuring the serum concentration of AST, ALT, TC, TG, HDL-C, LDL-C, and liver tissues were taken to make pathological sections for observation by optical microscope or were prepared for scanning electronic microscope.
  
  
  RESULTS
  The levels of AST, ALT, TC, TG, LDL-C were obviously decreased while HDL-C were increased in fatty liver rats by AC high dose. Meanwhile the cell morphology of liver tissues and the fenestraes of LSEC were improved as well.
  
  
  CONCLUSIONS
  AC can ameliorate the levels of blood lipid in fatty liver rats and improve the pathological change of liver tissues. To some extent AC has the function of prevention and treatment of fatty liver.
authors: School of Traditional Chinese Medicine,Southern Medical University, Guangzhou 510515, China. zqfimmu@163.com
authors: Qin
authors: Q
authors: Zhang
authors: Hong-bing
authors: HB
authors: Cai
authors: Zhi-xian
authors: ZX
authors: Mo
authors: Jue
authors: J
authors: Shi
authors: Xue-gang
authors: XG
authors: Sun
authors: Qiu-xian
authors: QX
authors: Peng
authors: Ming-hui
authors: MH
authors: Yang
mesh_terms: D029912:Abrus / Q000737:chemistry*; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D059305:Diet, High-Fat / Q000009:adverse effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005234:Fatty Liver / Q000097:blood / Q000378:metabolism / Q000517:prevention & control*; D005260:Female; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D010936:Plant Extracts / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D020011:Protective Agents / Q000302:isolation & purification / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014280:Triglycerides / Q000097:blood
chemical_list: D008055:Lipids; D010936:Plant Extracts; D020011:Protective Agents; D014280:Triglycerides; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase